Effect of second and third generation oral contraceptives on C-reactive protein, lipids and apolipoproteins in young, non-obese, non-smoking apparently healthy women

Clinical Biochemistry

Volumn 43, Issue 6, 2010, Pages 626-628

  Krintus, Magdalena ^a   Sypniewska, Grazyna ^a   Kuligowska Prusinska, Magdalena ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Apolipoprotein AI (ApoAI); Apolipoprotein B100 (ApoB); Cardiovascular disease (CVD); High sensitivity C reactive protein (hsCRP); Oral contraceptives (OC)

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; C REACTIVE PROTEIN; DESOGESTREL; GESTODENE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGE FACTORS; APOLIPOPROTEINS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; FEMALE; HEALTH; HUMANS; IDEAL BODY WEIGHT; LIPIDS; OBESITY; RISK FACTORS; SMOKING;

EID: 77950861579     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.12.013     Document Type: Article

References (11)

1. Shufelt C.h.L., Merz N.B. Contraceptive hormone use and cardiovascular disease. J. Am. Coll. Cardiol. 2009, 53(3).
2. Cauci S., Di Santolo M., Culhane J.F., Stel G., Gonano F., Guaschino S. Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet. Gynecol. 2008, 111:857-864.
3. Ridker P.M., Silvertown J.D. Inflammation, C-reactive protein, and atherothrombosis. J. Periodontol. 2008, 79(8 Suppl):1544-1551.
4. Walldius G., Jungner I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur. Heart J. 2005, 26:210-212.
5. Walldius G., Jungner I. Tha apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J. Intern. Med. 2006, 259:493-519.
6. van Rooijen M., Hansson L.O., Frostegård J., Silveira A., Hamsten A., Bremme K. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J. Thromb. Haemost. 2006, 4:77-82.
7. Viikari L.A., Huupponen R.K., Viikari J.S., Marniemi J., Eklund C., Hurme M., et al. Relationship between leptin and C-reactive protein in young Finnish adults. J. Clin. Endocrinol. Metab. 2007, 92:4753-4758.
8. Foulon T., Payen N., Laporte F., Bijaoui S., Dupont G., Roland F., et al. Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size. Contraception 2001, 64:11-16.
9. Gandotra P., Miller M. The role of triglycerides in cardiovascular risk. Curr. Cardiol. Rep. 2008, 10:505-511.
10. Ladeia A.M., Stefanelli E., Ladeia-Frota C., Moreira A., Hiltner A., Adan L. Association between elevated serum C-reactive protein and triglyceride levels in young subjects with type 1 diabetes. Diabetes Care 2006, 29:424-426.
11. Langlois M.R., Rietzschel E.R., De Buyzere M.L., De Bacquer D., Bekaert S., Blaton V., et al. Asklepios Investigators. Femoral plaques confound the association of circulating oxidized low-density lipoprotein with carotid atherosclerosis in a general population aged 35 to 55 years: the Asklepios Study. Arterioscler. Thromb. Vasc Biol. 2008, 28:1563-1568.